Amylin Protein as a Therapeutic Target in Alzheimer’s Disease

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Overview of Alzheimer’s Disease Pathology

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder in which numerous mechanisms contribute to disease progression. A defining feature is the accumulation of amyloid beta (Aβ) in the brain, which begins years before symptom onset. Aggregated Aβ forms extracellular plaques that exert neurotoxic effects, trigger neuroinflammation, and promote progressive neuronal death, ultimately impairing memory and other cognitive processes.

Amylin and Its Relationship to Aβ

Amylin, a peptide with structural and functional similarities to Aβ, has emerged as a significant factor in AD pathology. Both proteins form soluble oligomeric intermediates with pronounced cytotoxic potential. These intermediates disrupt cellular membranes and organelles, generate reactive oxygen species, and overwhelm protein degradation systems. Importantly, amylin and Aβ oligomers can co-aggregate, amplifying neurotoxicity. Elevated amylin levels have been identified not only in AD but also in dementia and type 2 diabetes mellitus, suggesting overlapping pathogenic mechanisms.

Role of Amylin Receptors in Disease Progression

Amylin receptors (AMY receptors) are expressed in neurons, glial cells, and endothelial cells, all of which are key to AD pathogenesis. AMY receptor activity has been implicated in synaptic dysfunction, neuronal loss, immune activation within the brain, and inflammatory cascades. Consequently, these receptors represent an important therapeutic target. Pharmacological modulation of AMY receptors, using antagonists or agonists, has demonstrated promising outcomes in preclinical and early clinical studies, including:

• Preservation of endothelial cell integrity
• Enhanced clearance of Aβ
• Reduction in neuroinflammation and microglial activation
• Improvement in synaptic connectivity
• Attenuation of neuronal dystrophy and apoptosis
• Restoration of cognitive performance
• Reduction in Aβ plaque deposition
• Ability to cross the blood–brain barrier
• Lower oxidative stress

Long-Term Potentiation and Cognitive Function

Long-term potentiation (LTP) is a critical process supporting stable synaptic signaling and memory. Accumulation of Aβ and amylin has been shown to disrupt LTP, contributing to cognitive decline. Studies in AD mouse models indicate that AMY receptor antagonism partially restores LTP and improves cognitive outcomes, further supporting the therapeutic relevance of this pathway.

Therapeutic Potential of Amylin Analogs

Amylin analogs, originally developed for metabolic indications such as obesity and type 2 diabetes, have demonstrated favorable safety profiles and efficacy in reducing body weight. When combined with glucagon-like peptide-1 (GLP-1) receptor agonists, these agents produce synergistic benefits, including enhanced weight reduction. Notably, GLP-1 receptor agonists are under investigation for AD treatment due to their ability to improve memory, promote Aβ clearance, and inhibit tau pathology.

Advances in Amylin-Based Therapeutics

Researchers have also explored the therapeutic use of fragments derived from the amylin receptor antagonist AC253. While the parent molecule is too large for efficient delivery, its fragmentation into two shorter peptides has enabled successful brain penetration. Once in the central nervous system, these fragments reassemble to form active AC253. In AD mouse models, daily administration for several weeks improved memory performance and reduced pathological brain changes, including Aβ-related damage.

Conclusion

Amylin and its receptors play a pivotal role in the pathogenesis of Alzheimer’s disease, paralleling and amplifying the effects of Aβ. Targeting the amylin pathway—through receptor modulation, analog administration, or novel peptide therapeutics—represents a promising avenue for disease modification. Continued translational research is warranted to validate these strategies and optimize their clinical application in AD management.

REFERENCES

1. Mathiesen, D. S., Lund, A., Holst, J. J., Knop, F. K., Lutz, T. A., & Bagger, J. I.(2022). Therapy of endocrine disease: Amylin and calcitonin–physiology and pharmacology. European Journal of Endocrinology, 186(6), R93-R111.
2.  Soudy, R., Kimura, R., Fu, W., Patel, A., & Jhamandas, J. (2022). Extracellular vesicles enriched with amylin receptor are cytoprotective against the Aß toxicity invitro. Plos one, 17(4), e0267164.
3. Soudy, R., Patel, A., Fu, W., Kaur, K., MacTavish, D., Westaway, D., … &Jhamandas, J. (2017). Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 3(1), 44-56.